Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
121 participants
INTERVENTIONAL
2018-12-26
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
NCT00556478
Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers
NCT00483990
Exploratory Study of Pagoclone in Men With Premature Ejaculation.
NCT00370981
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
NCT00219635
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
NCT00229073
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will also measure the effect of PSD502 on the Intravaginal Ejaculatory Latency Time (IELT). This is the time between when the penis enters the vagina and when the subject starts to ejaculate in the vagina.
Subjects are stratified based on whether they are circumcised or uncircumcised and within each stratified group subjects are randomized to PSD502 (lidocaine prilocaine spray) or placebo in a 1:1 ratio.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PSD502
PSD502 spray contains a eutectic-like mixture of lidocaine and prilocaine, and a propellant (norflurane) which also serves as a solvent. Each spray contains 7.5 mg lidocaine and 2.5 mg prilocaine. A single dose consists of 3 sprays applied to the glans penis.
PSD502
For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.
Study subjects should leave at least 24 hours between each dosing.
Placebo
The placebo is a metered dose spray, identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine (instead it contains PEG600 and Povidone).
Placebo
For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.
Study subjects should leave at least 24 hours between each dosing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.
Study subjects should leave at least 24 hours between each dosing.
PSD502
For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.
Study subjects should leave at least 24 hours between each dosing.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and aged 18 years and over.
* Diagnosed with PE according to the ISSM definition, that is, he ejaculates always or nearly always prior to or within about one minute of vaginal penetration; and is unable to delay ejaculation on all or nearly all vaginal penetrations; and experiences negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.
* Subject has lifelong PE from the first sexual experience.
* Subject must be in a stable heterosexual and monogamous relationship of at least 3 months' duration with this partner.
* Subject has at least documented 3 sexual encounters, each separated by an interval of at least 24 hours, in the baseline period.
* IELT ≤1 minute in all sexual encounters in the baseline period.
* The subject's partner must provide written informed consent, be aged 18 years or over and willing to comply with the study procedures.
* Subject indicates a level of Bother on Item 3 of the PEBEQ of either "moderately", "quite a bit" or "extremely" on all encounters during the baseline period.
* Subject registers a level of "bother" at a score of 4 or greater on an 11-point NRS scale at Screening to ensure that subjects not bothered by the quickness of their ejaculation are not entered into the baseline period.
Exclusion Criteria
* Subject has erectile dysfunction, defined as an IIEF-5 score of 21, unless the low score is entirely related to PE symptoms in the opinion of the Investigator.
* The subject, or his sexual partner, has a physical or psychological condition that would prevent them from undertaking the study procedures, including, but not limited to, the following:
1. Urological disease (e.g., prostatitis, urinary tract infection) or genitourinary surgery within 8 weeks of Screening.
2. Ongoing significant psychiatric disorder (e.g., bipolar disease, depression / anxiety disorder or schizophrenia) not controlled by medication.
* Subject has safety testing abnormalities at the Screening Visit, in particular liver function tests or anemia, that are indicative of a medical condition that would preclude further participation in the opinion of the Investigator.
* Subjects taking tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs) or selective serotonin reuptake inhibitors (SSRIs), for indications other than PE, where the dose has been changed within 4 weeks of Screening or it is planned that the dose will change during the treatment period.
* Subject has received any treatment for PE e.g., anti-depressant therapy, local anesthetic spray, eutectic mixture of local anesthetics (EMLA®) cream, intra-cavernosal injection, tramadol or psychotherapy within 4 weeks of Screening
* Subject, or his sexual partner, has a current history of alcohol or drug abuse, in the opinion of the Investigator.
* The subject, or his sexual partner, is unlikely to understand or be able to comply with study procedures, for whatever reasons.
* Subject, or his sexual partner, has known drug sensitivity to amide-type local anesthetics.
* Subjects with pregnant partners.
* Subject with sexual partners of child-bearing potential and not using appropriate contraception (hormonal contraception or intra-uterine device \[IUD\]).
* Subject, or his sexual partner, has a history of glucose-6-phosphate dehydrogenase (G 6 PD) deficiency or currently using medications that would increase susceptibility to methemoglobinemia (e.g., anti-malarial agents) or has congenital or acquired methemoglobinemia, or is at risk of industrial exposure to agents causing methemoglobinemia.
* Subject, or his sexual partner, uses Class I (e.g., mexiletine, tocainide) or III (e.g., amiodarone, sotalol) anti-arrhythmic drugs, or cimetidine, beta blockers or local anesthetics.
* Subject has received PSD502 in a clinical study or has received Fortacin within 1 year of Screening.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Plethora Solutions Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jed Kaminetsky, MD, BA
Role: PRINCIPAL_INVESTIGATOR
Manhattan Medical Research, 215 Lexington Avenue, 21st Floor, New York, NY 10016
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Achieve Clinical Research
Birmingham, Alabama, United States
Coastal Clinical Research
Mobile, Alabama, United States
Skyline Urology
Sherman Oaks, California, United States
Imagine Research of Palm Beach County
Boynton Beach, Florida, United States
SunCoast Research
Miami, Florida, United States
Suncoast Research Associates
Miami Lakes, Florida, United States
Clinical Research Center of Florida
Pompano Beach, Florida, United States
Primary Care Research
Atlanta, Georgia, United States
Georgia Clinical Research, Llc
Lawrenceville, Georgia, United States
Regional Urology, LLC
Shreveport, Louisiana, United States
Chesapeake Urology Research Associates
Towson, Maryland, United States
Boston Clinical Trials
Boston, Massachusetts, United States
Mens Health Boston
Chestnut Hill, Massachusetts, United States
Jubilee Clinical Research, Inc
Las Vegas, Nevada, United States
Accumed Research Associates
Garden City, New York, United States
Manhattan Medical Research Practice
New York, New York, United States
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York, United States
M3 Wake Research, Inc
Raleigh, North Carolina, United States
Midlantic Urology
Bala-Cynwyd, Pennsylvania, United States
Advanced Clinical Research - Jordan Ridge Family Medicine
Salt Lake City, Utah, United States
Advanced Clinical Research
West Jordan, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PSD502-PE-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.